Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) Operating Expenses (2016 - 2026)

Sanofi's Operating Expenses history spans 16 years, with the latest figure at -$4.8 billion for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 12.52% to -$4.8 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$44.2 billion, a 44.7% decrease, with the full-year FY2025 number at $21.6 billion, up 12.27% from a year prior.
  • Operating Expenses hit -$4.8 billion in Q1 2026 for Sanofi, up from -$20.2 billion in the prior quarter.
  • Over the last five years, Operating Expenses for SNY hit a ceiling of -$4.1 billion in Q1 2024 and a floor of -$20.2 billion in Q4 2025.
  • Historically, Operating Expenses has averaged -$8.2 billion across 5 years, with a median of -$4.6 billion in 2023.
  • Biggest five-year swings in Operating Expenses: rose 9.29% in 2024 and later plummeted 225.84% in 2025.
  • Tracing SNY's Operating Expenses over 5 years: stood at -$17.5 billion in 2022, then rose by 5.32% to -$16.6 billion in 2023, then decreased by 6.63% to -$17.7 billion in 2024, then dropped by 14.24% to -$20.2 billion in 2025, then skyrocketed by 76.43% to -$4.8 billion in 2026.
  • Business Quant data shows Operating Expenses for SNY at -$4.8 billion in Q1 2026, -$20.2 billion in Q4 2025, and -$14.4 billion in Q3 2025.